If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.
A new study finds that pathogenic germline variants (PGVs) in cancer predisposition genes like BRCA1 and BRCA2 increase the risk of multiple ...
Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
2dOpinion
It began when my phone rang while we were in the whale room at the American Museum of Natural History. My 5-year-old was ...
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
SEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCLCoverage leverages new Medicare episode pricing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback